AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
XARELTO has 17.7 points less BS than the average for Medical Devices, Pharma & Biotech.
Medical Devices, Pharma & Biotech BS: XARELTO (xarelto-us.com)
XARELTO’s website is a rare example of high-substance, low-fluff pharmaceutical communication that prioritizes patient utility over marketing jargon. Its score is only inflated by technical implementation gaps, specifically a total lack of structured data and minor heading hierarchy errors. It effectively replaces generic ‘breakthrough’ claims with verifiable financial support tiers and specific clinical mechanisms.
1. Deploy MedicalWebPage and Organization schema to the homepage and cost pages to repair the Identity and Authority gap. 2. Add an H1 tag to the homepage that mirrors the primary brand signal and core value proposition. 3. Include direct citations or outbound links to clinical trial data for each of the 10+ listed conditions (AFib, DVT, etc.). 4. Attach a specific source or date-stamp to the ’80 million’ prescription claim to convert it from a marketing statement to a verified proof point.
Information density is exceptionally high, with a power word saturation near 0%. Headings like H2 XARELTO has been prescribed more than 80 million times in the US alone and H3 Pay as little as $10* for your XARELTO prescription contain concrete numbers and named financial instruments rather than fluff. The body text provides technical specificity regarding the mechanism of action, specifically blocking Factor Xa, and defines DOACs (direct oral anticoagulants). Specific drug examples like Warfarin and Plavix are used for comparison, further grounding the content in medical substance.
AI only sees the HTML that arrives on first response — everything else is invisible. Expose your real text only footprint and find out which parts of your site never reach an AI crawler at all.
There is no detectable semantic drift across the analyzed pages. The homepage hero section promises information on how the drug works and cost support, which is delivered with extreme granularity on the What is XARELTO and XARELTO Cost pages respectively. The messaging regarding the $10 savings card and the 80 million prescription count remains consistent across all page discovery layers. The heading hierarchy is logical, moving from broad product identity to specific financial and clinical requirements.
Stop the ROI leak caused by technical debt and strategic misalignment. Conduct an Independent Strategic Diagnosis for 1 Euro to identify high impact issues across all audit categories.
The site avoids trust theatre by maintaining a review_count of 0, eschewing the fake testimonial patterns common in lower-tier medical marketing. However, it suffers from a lack of direct proof paths in the provided data; while it mentions 80 million prescriptions, it lacks a linked citation or footnote to a specific clinical registry or market report. The trust_theatre_flag is false, reflecting a lack of manipulative social proof displays.
Proof density is high regarding pricing and patient assistance programs, citing exact dollar amounts ($10, $3.33) and specific eligibility criteria for Medicare and Medicaid. Clinical proof is moderate; the site identifies the mechanism of action and indications but lacks outbound links to peer-reviewed studies or ClinicalTrials.gov registrations in the text. Verifiable evidence of financial support programs (Johnson & Johnson Patient Assistance) outpaces the clinical evidence provided in this patient-facing crawl.
To see how the system reconstructs a medical entity graph at scale, review the full Cleveland Clinic Structured Data audit. View the Cleveland Clinic Structured Data Audit for a live example of identity level decomposition and cross page entity mapping.
The site uses a standard pharmaceutical patient-resource template, including fingerprints like Patient Resources and Important Safety Information. While the structure is a commodity, the content is not; it provides a specific 30-day Trial Offer and a multi-tiered cost support breakdown that is unique to the brand. The industry jargon (e.g., pharmacovigilance concepts in the side effects list) is used as a technical deliverable rather than a marketing buzzword.
The largest authority gap is technical; the site lacks any structured data (schema_json is null), which is a failure to establish digital entity authority for a major pharmaceutical brand. There are no Person schema applications for medical reviewers or experts, resulting in a reliance on brand name alone for authority. The technical implementation is further weakened by a missing H1 tag on the homepage, despite the presence of high-quality meta descriptions.
Performance claims are limited to clinical efficacy and market scale, which are backed by specific figures like the 80 million prescriptions and the Factor Xa mechanism. There is no disconnect between the marketing tone and the technical reality provided. The site describes the increased risk of bleeding with clinical sobriety rather than minimizing it with marketing fluff.
Medical Devices, Pharma & Biotech BS: XARELTO (xarelto-us.com)
The site perfectly aligns with the Medical Pharma category, utilizing regulatory-compliant language such as FDA-approved, on-label use, and DOACs. It fulfills the industry requirement for clear indications and safety warnings.
Your site's meaning is determined by its graph, not its menus. Review the Internal Linking Architecture Framework to see how AI interprets nodes, edges, and authority flow inside your domain.
“The score of 23 is driven primarily by the Identity and Authority pillar (9/15) due to the absence of schema and technical heading errors. The site performed near-perfectly in Semantic Coherence (0/20) and exceptionally well in Information Density (5/30), where most business sites fail. The Commodity Fingerprint is low because the site provides specific technical and financial programs rather than boilerplate 'Why Choose Us' sections.”